Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score

OBJECTIVE: Using data from the SENSCIS trial, these analyses were undertaken to assess the effects of nintedanib versus placebo in subgroups of patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD), based on characteristics previously identified as being associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwana, Masataka, Allanore, Yannick, Denton, Christopher P., Distler, Jörg H. W., Steen, Virginia, Khanna, Dinesh, Matucci‐Cerinic, Marco, Mayes, Maureen D., Volkmann, Elizabeth R., Miede, Corinna, Gahlemann, Martina, Quaresma, Manuel, Alves, Margarida, Distler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306495/
https://www.ncbi.nlm.nih.gov/pubmed/34514739
http://dx.doi.org/10.1002/art.41965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306495/
https://www.ncbi.nlm.nih.gov/pubmed/34514739
http://dx.doi.org/10.1002/art.41965

Ejemplares similares